Ophthalmic Disease Therapeutics Market Global Industry Analysis

Posted by Rushikesh Pise on December 3rd, 2019

The Global Ophthalmic Disease Therapeutics Market will witness a steady growth due to the rise of ophthalmic diseases. According to a report published by Fortune Business Insights, titled “Ophthalmic Disease Therapeutics Market: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market was valued at US$ 29,504.8 Mn in 2018. Fortune Business Insights predicts that the global market will exhibit a CAGR of 6.1% and reach US$ 47,831.3 Mn by the end of 2026.

Browse Complete Report:


List of Companies leading the global Ophthalmic Disease Therapeutics Market include,

  •          Merck & Co. Inc.
  •          Pfizer Inc.
  •          Novartis AG
  •          F. Hoffmann-La Roche AG
  •          Regeneron Pharmaceuticals Inc
  •          Santen Pharmaceutical Co. Ltd
  •          Bayer AG
  •          Bausch & Lomb Inc

The National Eye Institute has projected that the rising population spends almost US$ 139 billion annually for vision disorders, and vision loss in the U.S. There has been an increasing number of cases of blindness around the worldwhich is the main factor for the growth in the global ophthalmic disease therapeutics market. The renowned pharmaceutical companies are constantly investing in the R&D of therapies in order to treat retinal disorders. Retinal disorders are expected to witness advanced therapies that are yet to be approved in the near future. The report provides an in-depth analysis of various factors contributing to the growth of the global ophthalmic disease therapeutics market.

Anti-inflammatory Drugs to Lead the Global Ophthalmic Disease Therapeutics Market

The global ophthalmic disease therapeutics market consists of numerous drug classes. They are: anti-inflammatory, anti-glaucoma, anti-VEGF, anti-infectives, and others. Amongst these drug classes, anti-inflammatory drugs were leading the global ophthalmic disease therapeutics market in 2018 with an impressive market share of 25.5%. It is projected to remain dominant throughout the entire forecast period. Fortune Business Insights predicts that several other factors such as improved reimbursement policies for eye care, and corticosteroids in ocular diseases are likely to boost the segment’s market during 2019-2026.

Moreover, there is another drug class in the global ophthalmic disease therapeutics market called as the anti-VEGF. The usage of anti-VEGF prevents the growth of vascular permeability factor. It is projected that this particular segment will witness a high CAGR between 2019 and 2026. For improvement of anti-VEGF activities, clinical trials are being conducted regularly on novel molecules. This has resulted in an increasing number of clinical trials which is likely to boost the anti-VEGF segment during the forecast period.


Like it? Share it!

Rushikesh Pise

About the Author

Rushikesh Pise
Joined: November 4th, 2019
Articles Posted: 81

More by this author